Decision support for organ offers in liver transplantation

Michael L. Volk, Nathan Goodrich, Jennifer C. Lai, Christopher Sonnenday, Kerby Shedden – 16 March 2015 – Organ offers in liver transplantation are high‐risk medical decisions with a low certainty of whether a better liver offer will come along before death. We hypothesized that decision support could improve the decision to accept or decline. With data from the Scientific Registry of Transplant Recipients, survival models were constructed for 42,857 waiting‐list patients and 28,653 posttransplant patients from 2002 to 2008.

Cilostazol improves hepatic blood perfusion, microcirculation, and liver regeneration after major hepatectomy in rats

Maximilian von Heesen, Stefan Dold, Simon Müller, Claudia Scheuer, Otto Kollmar, Martin K. Schilling, Michael D. Menger, Mohammed R. Moussavian – 13 March 2015 – Major hepatectomy or small‐for‐size liver transplantation may result in postoperative liver failure. So far, no treatment is available to improve liver regeneration. Herein, we studied whether cilostazol, a selective phosphodiesterase III inhibitor, is capable of improving liver regeneration after major hepatectomy.

Surgical results for recurrent hepatocellular carcinoma after curative hepatectomy: Repeat hepatectomy versus salvage living donor liver transplantation

Yo‐Ichi Yamashita, Yoshihiro Yoshida, Takeshi Kurihara, Shinji Itoh, Norifumi Harimoto, Toru Ikegami, Tomoharu Yoshizumi, Hideaki Uchiyama, Ken Shirabe, Yoshihiko Maehara – 13 March 2015 – The aims of this study were to evaluate the efficacy of repeat hepatectomy (Hx) and salvage living donor liver transplantation (LDLT) for recurrent hepatocellular carcinoma (HCC). A retrospective cohort study was performed to analyze the surgical results of repeat Hx and salvage LDLT for patients with recurrent HCC within the Milan criteria from 1989 to 2012.

Impact of anticoagulation on upper‐gastrointestinal bleeding in cirrhosis. A retrospective multicenter study

Federica Cerini, Javier Martínez Gonzalez, Ferran Torres, Ángela Puente, Meritxell Casas, Carmen Vinaixa, Marina Berenguer, Alba Ardevol, Salvador Augustin, Elba Llop, Maria Senosiaín, Càndid Villanueva, Joaquin de la Peña, Rafael Bañares, Joan Genescá, Júlia Sopeña, Agustín Albillos, Jaume Bosch, Virginia Hernández‐Gea, Juan Carlos Garcia‐Pagán – 12 March 2015 – Recent studies have shown that liver cirrhosis (LC) behaves as an acquired hypercoagulable state with increased thrombotic risk. This is why anticoagulation therapy (AT) is now frequently used in these patients.

Higher Mortality in registrants with sudden model for end‐stage liver disease increase: Disadvantaged by the current allocation policy

Allan B. Massie, Xun Luo, Jennifer L. Alejo, Anna K. Poon, Andrew M. Cameron, Dorry L. Segev – 12 March 2015 – Liver allocation is based on current Model for End‐Stage Liver Disease (MELD) scores, with priority in the case of a tie being given to those waiting the longest with a given MELD score. We hypothesized that this priority might not reflect risk: registrants whose MELD score has recently increased receive lower priority but might have higher wait‐list mortality. We studied wait‐list and posttransplant mortality in 69,643 adult registrants from 2002 to 2013.

Subscribe to